Influenza
Conditions
Keywords
influenza vaccine recombinant
Brief summary
This is a multicenter, escalating dose-ranging study to assess the safety, reactogenicity and immunogenicity of 3 different novel H1N1 influenza vaccine constructs delivered i.m. as a single dose vaccination on day 0.
Detailed description
VAX128-01 is a first in human study of three inactivated recombinant novel H1N1 influenza vaccines, designated VAX128 A, B and C. The purpose of the study is to compare the safety and immunogenicity of the three vaccines through a range of doses and to select one of the vaccines for further testing in phase II studies. We plan to assess the safety and immunogenicity in a dose escalating study. The study will enroll up to 100 healthy young adults (18-49 years) and 100 healthy adults than age 65 years. We are including the older adults in this phase 1 study because we have found that the elderly tolerated a vaccine similar to one of the candidates, VAX128A, better than young adults, but required a higher vaccine dose to achieve a similar antibody response. Nevertheless, because we are testing two other constructs (VAX128B and C), we will be making the conservative assumptions that the safety and immunogenicity data coming from the young adults will not predict the results in the elderly. Therefore, we will begin the study in the young adults and after the first three dose levels have been tested we will begin testing in the older adults. In this study we plan to enroll up to 100 young adults and up to 100 adults 65 years and older. The young adults will be most likely enrolled at one clinical site and the older adults will be enrolled at another clinical site. We plan to enroll a cohort of 10 young adults and 10 older adults every week. Each cohort will consist of 3 subjects to receive one of the three vaccines (9 subjects total) and one subject in each cohort will receive placebo. Dosing for the next cohort will be based on a two day assessment period after vaccination. The main part of the study will be conducted over 28 days and there will be two follow up phone calls at 6 months and one year.
Interventions
BIOLOGICALVAX128
one IM injection
BIOLOGICALPlacebo
One IM injection
Sponsors
VaxInnate Corporation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthy male or female aged 18 - 49 years or \>= 65 years * Give written informed consent * Females have a negative urine test for pregnancy before vaccination and use birth control during 28 day study period * Willing to receive the unlicensed (VAX128) vaccine given as an i.m. injection * Willing to provide multiple blood specimens collected by venipuncture
Exclusion criteria
* Chronic illness that would interfere with the subject's participation in the study or interpretation of the study results. * Impaired immune responsiveness * Received drugs effecting the immunity * Received or plan to receive a nonstudy vaccine within 30 days prior to vaccination and during the study, including licensed influenza vaccines. * History of anaphylactic type reaction to injected vaccines. * History of drug abuse in the year prior to screening. * History of Guillain-Barré Syndrome. * Receipt or donation of blood products * Acute disease within 72 hours prior to vaccination * History of heart or lung disease * Has other conditions that might interfere with study objectives.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety | 28 days | Assess safety, reactogenicity and tolerability. Symptoms will be collected from the memory aid and from the information collected at the clinic visits. All symptoms will be graded according to severity. Response to vaccine will be categorized as local (arm pain, redness, bruising etc) or systemic (headache, muscle aches, fatigue, etc) symptoms. Laboratory tests such as CRP, WBC, LFTs and cytokines collected before and after vaccination will also be analyzed. We will compare the types and severity of symptoms and laboratory results based on vaccine construct or placebo. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity | 28 days | To assess serm immune response, sera collected at Day 0 (pre-vaccination), 7, 14 and 28 will be analyzed for HAI, serum IgG anti-HA by ELISA and serum IgG anti-flagellin by ELISA. The geometric mean, seroconversion and seroprotection rates will be determined. |
Countries
United States
Outcome results
None listed